Antineutrophil cytoplasmic antibody-associated crescentic glomerulonephritis with membranous nephropathy treated using thiamazole

被引:0
|
作者
Kakita, Tomoko [1 ]
Nagatoya, Katsuyuki [1 ]
Takimoto, Hiroki [1 ]
Matsuda, Hirohisa [1 ]
Mori, Tatsuhiko [1 ]
Kawaguchi, Ayako [1 ]
Inoue, Toru [1 ]
机构
[1] Osaka Med Coll Hosp, Dept Nephrol, 2-7 Daigaku machi, Takatsuki, Osaka 5698686, Japan
来源
CEN CASE REPORTS | 2013年 / 2卷 / 02期
关键词
ANCA-associated crescenticglomerulonephritis; Membranous nephropathy; Antithyroid drug;
D O I
10.1007/s13730-013-0060-7
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
A 21-year-old woman with nephrotic syndrome was referred to our hospital. She had congenital diaphragmatic hernia, hypoxic ischemic encephalopathy, and mental retardation, and had been treated for hyperthyroidism with thiamazole in another hospital. Serum creatinine was 37.8 lmol/L and antineutrophil cytoplasmic antibody against myeloperoxidase (MPO-ANCA) was 39 EU. Urinalyses were 3? for proteins and 3? for occult blood. A renal biopsy was performed. An examination using light microscopy (LM) revealed necrotizing glomerulonephritis with crescent formation. Immunofluorescence microscopy showed granular staining with immunoglobulin G and complement component 3 along the capillary walls. Electron microscopy (EM) disclosed subepithelial dense deposits. A renal biopsy suggested necrotizing glomerulonephritis with membranous nephropathy (MN) in stages I or II. Since many cases of drug- induced ANCA-associated glomerulonephritis (AAG) have been reported, we stopped thiamazole and treated with corticosteroid. The MPOANCA titer became negative 49 days after the initiation of treatment. Two years after the first treatment, the MPOANCA titer became elevated again and was 82 EU. The patient was administered cyclophosphamide and prednisone. However, the MPO- ANCA titer did not decrease. A renal biopsy was performed again 3 years after the first renal biopsy. LM revealed no crescentic formation but demonstrated spike formations along the glomerular basement membrane. EM also disclosed subepithelial dense deposits, but less than the first biopsy. The renal biopsy suggested MN in stages II or III. AAG was regarded as inactive after corticosteroid treatment. Therefore, ciclosporin administration was started. In conclusion, we experienced a rare case of AAG complicated with MN. The histopathologic results showed that immunosuppressive therapy seemed to be effective in treating crescentic glomerulonephritis; furthermore, it reduced proteinuria but could not reduce the MPO-ANCA titer.
引用
收藏
页码:165 / 169
页数:5
相关论文
共 47 条
  • [31] A case of anti-GBM glomerulonephritis superimposed on HBV-associated membranous nephropathy
    Takeshi Yamamoto
    Susumu Oseto
    Natsuko Imakita
    Masami Inada
    Megumu Fukunaga
    CEN Case Reports, 2013, 2 (2) : 239 - 247
  • [32] Development of Myeloperoxidase Anti-neutrophil Cytoplasmic Antibody-positive Necrotizing Crescentic Glomerulonephritis in an Elderly Patient with Immunological Kidney Disease
    Yoshida, Haruyoshi
    Takahashi, Naoki
    Horiguchi, Takayasu
    Yasuhara, Hiroki
    Tanaka, Tokuharu
    Chen, Yuhao
    Takasaki, Toshikazu
    Tsukao, Hitokazu
    Yoshida, Michiko
    Kawakami, Satoshi
    Ohta, Makoto
    Naiki, Hironobu
    Konishi, Satoshi
    Ito, Isao
    Iwano, Masayuki
    INTERNAL MEDICINE, 2021, 60 (24) : 3927 - 3935
  • [33] Nomogram for thromboembolic events in primary membranous nephropathy associated with PLA2R antibody
    Zihan Zhai
    Yanhong Guo
    Lu Yu
    Yulin Wang
    Liuwei Wang
    Qiuhong Li
    Yapei Yuan
    Lin Tang
    Scientific Reports, 15 (1)
  • [34] Antibody-Guided Therapy in Phospholipase A2 Receptor-Associated Membranous Nephropathy
    Vink, Coralien H.
    van de Logt, Anne-Els
    van der Molen, Renate G.
    Hofstra, Julia M.
    Wetzels, Jack F. M.
    KIDNEY INTERNATIONAL REPORTS, 2023, 8 (03): : 432 - 441
  • [35] Membranous nephropathy associated with immunoglobulin G4-related disease successfully treated with obinutuzumab
    Ginthoer, Noemi E.
    Artinger, Katharina
    Pollheimer, Marion J.
    Stradner, Martin H.
    Eller, Kathrin
    CLINICAL KIDNEY JOURNAL, 2022, 15 (03) : 564 - 566
  • [36] A case of treatment-resistant membranous nephropathy associated with graft versus host disease successfully treated with daratumumab
    Benoit, Stefanie W.
    Khandelwal, Pooja
    Grimley, Michael S.
    PEDIATRIC TRANSPLANTATION, 2022, 26 (04)
  • [37] Membranous nephropathy associated with multicentric Castleman's disease that was successfully treated with tocilizumab: a case report and review of the literature
    Saiki, Ryosuke
    Katayama, Kan
    Hirabayashi, Yosuke
    Oda, Keiko
    Fujimoto, Mika
    Murata, Tomohiro
    Nakajima, Ayako
    Dohi, Kaoru
    BMC NEPHROLOGY, 2021, 22 (01)
  • [38] Membranous nephropathy associated with pregnancy: an anti-phospholipase A2 receptor antibody-positive case report
    Uchino, Eiichiro
    Takada, Daisuke
    Mogami, Haruta
    Matsubara, Takeshi
    Tsukamoto, Tatsuo
    Yanagita, Motoko
    CEN CASE REPORTS, 2018, 7 (01): : 101 - 106
  • [39] Primary antiphospholipid syndrome associated with anti-phospholipase A2 receptor antibody-positive membranous nephropathy
    Maxime Teisseyre
    Hélène Perrochia
    Pascal Reboul
    Sylvain Cariou
    Sophie Renaud
    Cédric Aglae
    Olivier Moranne
    BMC Nephrology, 21
  • [40] Primary antiphospholipid syndrome associated with anti-phospholipase A2 receptor antibody-positive membranous nephropathy
    Teisseyre, Maxime
    Perrochia, Helene
    Reboul, Pascal
    Cariou, Sylvain
    Renaud, Sophie
    Aglae, Cedric
    Moranne, Olivier
    BMC NEPHROLOGY, 2020, 21 (01)